Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Biomay AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Biomay AG - Product Pipeline Review - 2014', provides an overview of the Biomay AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Biomay AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Biomay AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Biomay AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Biomay AG's pipeline products Reasons to buy - Evaluate Biomay AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Biomay AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Biomay AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Biomay AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biomay AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Biomay AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Biomay AG Snapshot 5 Biomay AG Overview 5 Key Information 5 Key Facts 5 Biomay AG - Research and Development Overview 6 Key Therapeutic Areas 6 Biomay AG - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Out-Licensed Products 10 Out-Licensed Products/Combination Treatment Modalities 11 Biomay AG - Pipeline Products Glance 12 Biomay AG - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Biomay AG - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Biomay AG - Drug Profiles 15 BM-32 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Fish Hypoallergenic Vaccine 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 BM-10 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 BM-31 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Japanese Cedar Hypoallergenic Vaccine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Oligonucleotide for Grass Allergy 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Ragweed Hypoallergenic Vaccine 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Subunit Vaccine for Cat Allergy 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Subunit Vaccine for Mite Allergy 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Subunit Vaccine for Ragweed Allergy 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Vaccine for Grass Allergy 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Biomay AG - Pipeline Analysis 27 Biomay AG - Pipeline Products by Route of Administration 27 Biomay AG - Pipeline Products by Molecule Type 28 Biomay AG - Recent Pipeline Updates 29 Biomay AG - Dormant Projects 30 Biomay AG - Locations And Subsidiaries 31 Head Office 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 33 Disclaimer 33
List of Tables Biomay AG, Key Information 5 Biomay AG, Key Facts 5 Biomay AG - Pipeline by Indication, 2014 7 Biomay AG - Pipeline by Stage of Development, 2014 8 Biomay AG - Monotherapy Products in Pipeline, 2014 9 Biomay AG - Out-Licensed Products in Pipeline, 2014 10 Biomay AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 11 Biomay AG - Phase II, 2014 12 Biomay AG - Phase I, 2014 13 Biomay AG - Preclinical, 2014 14 Biomay AG - Pipeline by Route of Administration, 2014 27 Biomay AG - Pipeline by Molecule Type, 2014 28 Biomay AG - Recent Pipeline Updates, 2014 29 Biomay AG - Dormant Developmental Projects,2014 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.